CAMP4 THERAPEUTICS CORPORATION
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Ticker
- CAMP
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joshua Mandel-Brehm
- Headquarters
- One Kendall Square, Cambridge, MA, United States, 02139
- Employees
- 48
- Website
- camp4tx.com
Metrics
Analyst Insights & forecasts
Based on information from 10 analysts.
Earnings per share (EPS) forecast
| Q3 • 25 | Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|---|
| Actual | -$0.54 | -$0.23 | -$0.21 | -$0.22 |
| Expected | -$0.48 | -$0.27 | -$0.21 | -$0.24 |
| Surprise | -12.50% | 16.37% | - | 8.33% |
| Missed | Beat | Beat | Current |
Financial Performance
| Q1 • 26 | Q2 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $1.3M | $1.8M | 37.48% |
| Net income | $-18.3M | $-33.5M | 82.91% |
| Profit margin | -1,416.62% | -1,884.77% | 33.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a CAMP4 THERAPEUTICS CORPORATION share?
CAMP4 THERAPEUTICS CORPORATION shares are currently traded for undefined per share.
02How many shares does CAMP4 THERAPEUTICS CORPORATION have?
CAMP4 THERAPEUTICS CORPORATION currently has 62.8M shares.
03Does CAMP4 THERAPEUTICS CORPORATION pay dividends?
No, CAMP4 THERAPEUTICS CORPORATION doesn't pay dividends.
04What is CAMP4 THERAPEUTICS CORPORATION 52 week high?
CAMP4 THERAPEUTICS CORPORATION 52 week high is $7.75.
05What is CAMP4 THERAPEUTICS CORPORATION 52 week low?
CAMP4 THERAPEUTICS CORPORATION 52 week low is $2.90.
06What is the 200-day moving average of CAMP4 THERAPEUTICS CORPORATION?
CAMP4 THERAPEUTICS CORPORATION 200-day moving average is $4.20.
07Who is CAMP4 THERAPEUTICS CORPORATION CEO?
The CEO of CAMP4 THERAPEUTICS CORPORATION is Joshua Mandel-Brehm.
08How many employees CAMP4 THERAPEUTICS CORPORATION has?
CAMP4 THERAPEUTICS CORPORATION has 48 employees.
09What is the market cap of CAMP4 THERAPEUTICS CORPORATION?
The market cap of CAMP4 THERAPEUTICS CORPORATION is $233M.
10What is the P/E of CAMP4 THERAPEUTICS CORPORATION?
The current P/E of CAMP4 THERAPEUTICS CORPORATION is null.
11What is the EPS of CAMP4 THERAPEUTICS CORPORATION?
The EPS of CAMP4 THERAPEUTICS CORPORATION is -$2.32.
12What is the PEG Ratio of CAMP4 THERAPEUTICS CORPORATION?
The PEG Ratio of CAMP4 THERAPEUTICS CORPORATION is null.
13What do analysts say about CAMP4 THERAPEUTICS CORPORATION?
According to the analysts CAMP4 THERAPEUTICS CORPORATION is considered a buy.
